

Manuscript for submission

## Title Page

### Kidney Protection During Surgery on the Thoracoabdominal Aorta: A Systematic Review

(<6500 words)

## Authors

Mr James Thomas Bennett<sup>1,2</sup>

Mrs Sarah Shirley<sup>1,2</sup>

Dr Bettina Wilm<sup>2</sup>

Professor Patricia Murray<sup>2</sup>

Professor Mark Field<sup>1,2</sup>

1. Liverpool Heart and Chest Hospital NHS Trust, Liverpool, L14 3PE, England
2. The University of Liverpool

**Keywords:** Thoracoabdominal Surgery, Aorta, Kidney, Protection, Renal, Perfusion

## Glossary

AKI- Acute kidney injury

ATN- Acute tubular necrosis

ATP- Adenosine Triphosphate

CPB- Cardiopulmonary bypass

DAP- Distal aortic perfusion

DHCA- Deep hypothermic circulatory arrest

ECC- Extracorporeal circulation

EU- European Union

HLM- Heart lung machine

IRI- Ischaemia-reperfusion injury

KDIGO- Kidney disease improving global outcomes

LHB- Left heart bypass

pCPB- Partial cardiopulmonary bypass

POS- Prospective observational study

PRISMA- Preferred reporting items for systematic reviews and meta-analyses

RCT- Randomised controlled trial

ROB- Risk of bias

ROS- Retrospective observational study

RRT- Renal replacement therapies

SACC- Simple aortic cross clamping

SRP- Selective renal perfusion

SWiM- Synthesis without meta-analysis

TAA- Thoracoabdominal aorta

Manuscript for submission

Abstract (300/300 words)

**Objectives:** Post-operative acute kidney injury (AKI) is a common complication of surgery to repair the thoracoabdominal aorta, and is associated with increased risks of dialysis and early mortality. Perfusion techniques are routinely used during surgery to reduce renal injury. We conducted a systematic review of renal and mortality outcomes by perfusion technique, to evaluate their effectiveness in providing kidney protection.

**Methods:** We searched PubMed, Web of Science, ClinicalTrials.gov and ClinicalTrialsRegister.EU to identify relevant studies published from 1995 to 2023. Included studies were quality assessed, and data extracted. Findings of the highest quality studies were used to synthesise a narrative discussion.


**Results:** 44 studies were included in our analysis, featuring three systemic perfusion strategies: Left heart bypass (LHB; n=24), cardiopulmonary bypass with deep hypothermic circulatory arrest (DHCA; n=17), and partial cardiopulmonary bypass (pCPB; n=11). Three categories of selective renal perfusion (SRP) strategy were identified: Warm blood, cold blood and cold crystalloid. Our analysis found that operative mortality was 0-22.0% following LHB, 2.2-12.5% following DHCA and 0-42.1% following pCPB. The incidence of post-operative renal replacement therapy (RRT) was 0-40.0% following LHB, 0-13.8% following DHCA and 0-31.6% following pCPB.

**Conclusions:** Intra-operative perfusion strategies can facilitate kidney protection through improved oxygenation or hypothermic preservation. Distal aortic perfusion (DAP), with LHB or pCPB, is associated with lower rates of dialysis and operative mortality than simple aortic cross clamping. Whilst DHCA is associated with low rates of AKI, its use has not been evaluated through high-quality research. For extensive aneurysm repairs, adjunctive SRP with cold blood or crystalloid fluids is shown to enhance kidney protection during DAP, whereas warm blood SRP is associated with increased rates of AKI and operative mortality. We identify the optimisation of warm blood SRP and the attenuation of intravascular haemolysis as urgent areas of research to address the problem of AKI.

Manuscript for submission

## Introduction

Surgical repair of the thoracoabdominal aorta (TAA) is a challenging procedure that exposes patients to aberrant physiological conditions including organ ischaemia, hypothermia and increased vascular resistance. Such factors can contribute to the development of post-operative organ dysfunction, manifesting as disorders such as acute kidney injury (AKI), paraplegia, stroke or pulmonary dysfunction. Several key advances in clinical practices have improved intra-operative organ protection over time, yielding significant reductions in the incidence of operative morbidity and mortality. For instance, distal aortic perfusion, cerebrospinal fluid drainage and intra-operative neuromonitoring can be credited with improvements in spinal cord protection<sup>1-4</sup>. However, providing effective intra-operative renal protection remains an elusive ambition. Despite numerous attempts to perfuse the kidneys with blood or crystalloid fluids, the risk of post-operative AKI remains high.



**Figure 1. The thoracoabdominal aorta following Crawford extent II repair.**

Manuscript for submission

AKI denotes an abrupt decline in renal function, diagnosed by an elevated serum creatinine concentration or decreased urine output (table 1)<sup>5</sup>. Severe AKI requires the use of RRT, and is associated with an increased risk of early mortality<sup>6-8</sup>. Furthermore, approximately 8% of patients who develop AKI progress towards end-stage renal dysfunction and require life-long renal care<sup>9-11</sup>. To provide effective kidney protection requires an appreciation of the multifactorial nature of renal injury. By understanding its pathophysiological development, we can develop targeted strategies for the amelioration of AKI.

**Table 1: KDIGO AKI Classification Criteria for Adults<sup>19</sup>**

Stage	Serum creatinine	Urine output
<b>1</b>	1.5-1.9 times baseline OR ≥0.3mg/dl (≥26.5mmol/l) increase	<0.5ml/kg/h for 6-12 hours
<b>2</b>	2.0-2.9 times baseline	<0.5ml/kg/h for ≥12 hours
<b>3</b>	3.0 times baseline OR ≥4.0mg/dl (≥353.6mmol/l) OR Initiation of renal replacement therapy	<0.3ml/kg/h for ≥24 hours OR Anuria for ≥12 hours

Renal ischaemia is a significant cause of AKI, initiated by clamping of the suprarenal aorta. Whilst clamping facilitates aortic transection and repair, it also halts blood flow to the kidneys, creating conditions of hypoxia that can damage cells and lead to renal dysfunction. Tubular reabsorption and secretion, for instance, require tubular epithelial cells to receive a sufficient delivery of oxygen to sustain oxidative phosphorylation<sup>5,12-14</sup>. Extended periods of ischaemia can produce cell death through apoptosis and acute tubular necrosis (ATN)<sup>5</sup>. Furthermore, subsequent re-perfusion of the hypoxic kidney, on removal of the aortic cross-clamp, can amplify the mitochondrial production of reactive oxygen species and stimulate an

## Manuscript for submission


inflammatory cascade<sup>15,16</sup>. These processes can culminate in cell damage and dysfunction, collectively known as ischaemia-reperfusion injury (IRI)<sup>12,16</sup>. The historic technique of ‘simple aortic cross clamping’ (SACC), which involves no form of systemic circulatory support, exposes the kidneys to an inevitable period of ischaemia, risking injury<sup>17,18</sup>.

### Intra-operative Kidney Protection

The underlying principle of intra-operative kidney protection is to minimise renal IRI through sustained oxygen delivery or protective hypothermia. These objectives can be achieved firstly through systemic circulatory support strategies to maintain general systemic blood flow, and, if necessary, the additional use of selective renal perfusion (SRP) to maintain fluid/blood supply to the kidneys. These techniques can be achieved with the use of the heart lung machine (HLM) (figure 2).

During the period of aortic cross clamping, strategies of left heart bypass (LHB) or partial cardiopulmonary bypass (pCPB) can be used to provide a flow of normothermic, oxygen-rich blood to the distal aorta, legs and visceral organs. Alternatively, cardiopulmonary bypass with deep hypothermic circulatory arrest (DHCA) can be used to provide systemic hypothermia and enable arrest of the circulation. DHCA is commonly used for emergency TAA repairs, or cases in which application of an aortic cross clamp is not feasible.

Manuscript for submission



**Figure 2. Strategies of circulatory support and selective renal perfusion used during TAA repair. Circulatory support strategies require the use of the heart lung machine for systemic blood flow. Selective renal perfusion involves direct cannulation and perfusion of the renal arteries, and may be used alongside, or independently of, strategies of systemic circulatory support.**

All systemic perfusion strategies can be supplemented with the use of SRP. Through direct cannulation of the renal arteries, the kidneys can be perfused with warm blood, cold blood or cold crystalloid fluids. 'Warm' SRP, delivered at normothermia to mild hypothermia, is intended to maintain renal oxygen delivery; 'cold' SRP, routinely cooled to approximately 4°C, aims to reduce renal oxygen consumption. Warm perfusion solutions therefore contain blood to facilitate oxygen delivery, whereas cold solutions can be composed of blood and/or crystalloid fluids. Crystalloid perfusates are commonly enriched with

Manuscript for submission

additives designed to increase buffering capacity, provide cell membrane integrity or reduce inflammation (table 5)<sup>19</sup>.

There is no clinical consensus as to what strategies of circulatory support or SRP should be used to provide effective intra-operative kidney protection. There is also limited guidance on the management of all strategies, despite the known risks of cardiac arrest associated with the use of cold perfusion solutions. As a result, various methods remain in use, and AKI continues to negatively impact patient quality of life and impose a burden on healthcare resources. To identify best practice and drive innovation in kidney protection, we must evaluate the efficacy of intra-operative perfusion techniques.

This systematic review provides a comprehensive analysis of renal and mortality outcomes associated with all perfusion strategies used during TAA surgery. It catalogues the findings of relevant studies published between the years 1995 and 2023, and evaluates the quality of evidence regarding the use of each technique within a narrative discussion. Finally, we identify encouraging areas of research for the future innovation of renal protection.

## **Materials and Methods**

### Study Protocol and Literature Search

Our protocol was prospectively registered with Prospero (CRD42020166428) and designed in accordance with PRISMA and SWiM recommendations. A search of PubMed, Web of Science, ClinicalTrials.gov and the EU Clinical Trials Register was conducted to identify relevant English language studies published between 1995 and 2023. Studies were screened against eligibility criteria at the abstract and full-text stages. Included studies were required to feature open surgery on the TAA, an adult patient population, the use of circulatory support, and reporting of post-operative renal outcomes. Studies containing the predominant use of endovascular techniques or type A dissection repairs were excluded. Clinical trials (CT)

Manuscript for submission

and observational studies were included, whereas single case studies and non-primary publications were excluded. Full literature search terms are provided in supplementary table S1.

### Data Extraction and Analysis

Data extraction was performed by two reviewers (JB & SS) to ensure consensus in recorded outcomes. Study characteristics, patient demographics, intervention details and clinical outcomes were extracted. Outcomes included the incidence of post-operative RRT, AKI, 30-day mortality and in-hospital mortality. Where appropriate, patient subgroups were identified within studies according to the predominant perfusion strategies used. Data were extracted and presented according to patient subgroups, to facilitate the comparison of renal and mortality outcomes according to the techniques used. Meta-analysis was not undertaken due to the recognised variability in patient characteristics, operative techniques and reported outcomes present in this area of research.

### Assessment of Quality and Risk of Bias

A quality and risk of bias (QROB) assessment was undertaken according to nine criteria: Directness to the review aims, research design and methodology, representativity of patient characteristics, risk of participant duplication across multiple publications from the same institution or author, appropriate use of statistical analysis, certainty of findings (based on sample size and magnitude of results), standardisation of operative procedures, reporting of perfusion strategies, and potential conflicts of interest. Studies were judged to present 'no concerns', 'minor concerns' or 'major concerns' for each QROB criterion. For single cohort observational studies, a judgement of 'not applicable' was used in regard to the 'appropriate use of statistical analysis'. The overall quality of each study was summarised as 'very high', 'high', 'moderate' or 'low', based on the number of respective concerns identified (table 2). Following the QROB assessment, a narrative discussion was synthesised, prioritising the findings of the highest quality studies.



Manuscript for submission

<b>Overall Quality</b>	<b>Number of minor concerns</b>	<b>Number of major/not applicable concerns</b>
Very High	≤1	0
High	2-3	0
Moderate	≤3	1
Low	>3	≥1

## Results

### Study Characteristics

Of 573 identified studies, 44 were suitable for inclusion, featuring a combined total of 6,582 operative cases, as displayed in the PRISMA flow diagram of the literature search and screening process (figure 3). The included studies consisted of 3 clinical trials, 7 prospective observational studies (POS) and 34 retrospective observational studies (ROS). 67 study subgroups were identified according to perfusion strategy. 22 studies featured multiple patient cohorts, enabling the direct comparison of alternate perfusion strategies, whereas 22 studies featured a single patient group. An overview of participant characteristics is presented in table 4, and study findings are summarised in table 6.




Figure 3. PRISMA flow diagram of the literature search and screening process.

### Quality and Risk of Bias Assessment

The QROB assessment showed that five studies were of ‘very high quality’, three studies of ‘high quality’, ten studies of ‘moderate quality’ and twenty-five of ‘low quality’ (table 3). No significant conflicts of interest were identified.

Manuscript for submission

Study	Assessment Criteria									Summary of Quality Assessment
	Focus on renal outcomes	Study design/ methodology	Patient characteristics	Risk of participant duplication across studies	Appropriate statistical analysis	Certainty of findings	Standardisation of operative procedures	Detailed perfusion strategies	Conflicts of interest	
Safi <i>et al.</i> (1996)	✓	⚠	✓	✓	✓	✓	✓	✓	✓	Very High
Koksoy <i>et al.</i> (2002)	✓	✓	✓	✓	✓	⚠	✓	✓	✓	Very High
Lemaire <i>et al.</i> (2009)	✓	✓	✓	✓	✓	✓	✓	✓	✓	Very High
Kahlberg <i>et al.</i> (2021)	✓	✓	✓	✓	✓	✓	✓	✓	✓	Very High
Henmi <i>et al.</i> (2022)	✓	⚠	✓	✓	✓	✓	✓	✓	✓	Very High
LeMaire <i>et al.</i> (2002)	⚠	⚠	✓	✓	✓	⚠	✓	✓	✓	High
Hassoun <i>et al.</i> (2004)	✓	⚠	⚠	✓	✓	✓	✓	✓	✓	High
Conrad <i>et al.</i> (2011)	⚠	⚠	✓	✓	✓	✓	✓	⚠	✓	High
Bavaria <i>et al.</i> (1995)	⚠	⚠	⚠	✓	✓	✓	✓	✗	✓	Moderate
Morishita <i>et al.</i> (1999)	✓	⚠	✗	✓	✓	⚠	✓	✓	✓	Moderate
Schepens <i>et al.</i> (1999)	⚠	⚠	✗	✓	✓	✓	✓	✓	✓	Moderate
Kunihara <i>et al.</i> (2009)	✓	✓	✓	✓	⚠	⚠	✓	✓	✓	Moderate
Weiss <i>et al.</i> (2012)	⚠	⚠	✓	✓	✓	✓	⚠	✗	✓	Moderate
Tshomba <i>et al.</i> (2014)	✓	⚠	✓	✓	✓	✓	✗	✓	✓	Moderate
Wahlgren <i>et al.</i> (2017)	⚠	⚠	✗	✓	✓	✓	✓	⚠	✓	Moderate
Zhang <i>et al.</i> (2019)	⚠	⚠	⚠	✗	✓	✓	✓	✓	✓	Moderate
Harky <i>et al.</i> (2021)	⚠	⚠	✗	✓	✓	✓	⚠	✓	✓	Moderate
Karlsson <i>et al.</i> (2022)	⚠	✓	✓	✓	✓	✗	⚠	✓	✓	Moderate
Jacobs <i>et al.</i> (1998)	✓	✓	⚠	✓	✗	✗	✓	✓	✓	Low
Leijdekkers <i>et al.</i> (1999)	✓	✓	⚠	✓	✗	✗	✓	✓	✓	Low
Mastroroberto <i>et al.</i> (1999)	⚠	⚠	✗	✓	⚠	✗	✓	✗	✓	Low
Welborn <i>et al.</i> (2000)	✓	✓	✗	✓	✓	⚠	⚠	✗	✓	Low
Cina <i>et al.</i> (2002)	⚠	✓	✗	✓	✗	✗	✗	✗	✓	Low
Kawaharada <i>et al.</i> (2002)	✗	⚠	✗	✗	✓	⚠	✓	✓	✓	Low
Kawaharada <i>et al.</i> (2004)	⚠	⚠	✗	✗	✓	✓	✓	✓	✓	Low
Nishi <i>et al.</i> (2004)	⚠	⚠	✓	✓	✗	✗	✓	✓	✓	Low
Palombo <i>et al.</i> (2004)	⚠	⚠	✓	✓	✗	✗	✓	✓	✓	Low
Fleck <i>et al.</i> (2005)	✗	⚠	✗	✓	⚠	⚠	✓	✓	✓	Low
Soukiasian <i>et al.</i> (2005)	⚠	⚠	✗	✓	⚠	✓	⚠	✗	✓	Low
Fehrenbacher <i>et al.</i> (2007)	⚠	⚠	✗	✗	⚠	⚠	✓	✓	✓	Low
Fehrenbacher <i>et al.</i> (2007)	✓	⚠	✗	✗	⚠	✗	✓	✓	✓	Low
Fehrenbacher <i>et al.</i> (2010)	⚠	⚠	✓	✗	⚠	✓	✓	✓	✓	Low
Kulik <i>et al.</i> (2011)	⚠	⚠	✓	✗	⚠	⚠	✓	✓	✓	Low
Corvera <i>et al.</i> (2012)	⚠	✗	✓	✗	⚠	✓	✓	✓	✓	Low
Kouchoukos <i>et al.</i> (2013)	⚠	⚠	✓	✗	⚠	⚠	✓	✓	✓	Low
Kouchoukos <i>et al.</i> (2015)	⚠	⚠	✗	✗	⚠	⚠	✓	✓	✓	Low
Wongkorrat <i>et al.</i> (2015)	✗	✗	✓	✓	⚠	⚠	⚠	⚠	✓	Low
Zhang <i>et al.</i> (2016)	✗	⚠	⚠	✓	⚠	⚠	✓	✓	✓	Low
Alfonsi <i>et al.</i> (2018)	⚠	⚠	✓	✓	✗	✓	✓	⚠	✓	Low
Mkalaluh <i>et al.</i> (2018)	⚠	⚠	✓	✓	⚠	✗	✗	⚠	✓	Low
Kouchoukos <i>et al.</i> (2019)	⚠	⚠	✓	✗	⚠	✓	✓	✓	✓	Low
Kunihara <i>et al.</i> (2021)	✗	⚠	✓	✓	⚠	⚠	✗	✓	✓	Low
Huang <i>et al.</i> (2022)	⚠	⚠	✗	✓	⚠	⚠	✓	✓	✓	Low
Bianchi <i>et al.</i> (2022)	✗	⚠	✓	✓	⚠	⚠	✓	✗	✓	Low
<b>Key:</b>	✓	No concerns	⚠	Minor concerns	✗	Major concerns	⚠	Not applicable		

Table 3: Visualisation of QROB assessment for all included studies.

Manuscript for submission

**Table 4: Clinical heterogeneity of included studies**

Study	n	DTA	TAA Extent					Emergency Operations	Pre-operative CKD	Male	Mean Age (Yrs)
			I	II	III	IV	V				
Alfonsi <i>et al.</i> 2018	217	0.0	30.4	52.1	11.5	4.6	1.4	8.8		68.2	60.2
Bavaria <i>et al.</i> 1995	81		32.1	22.2	9.9	9.9		30.9			
Bianchi <i>et al.</i> 2022	100	0.0	16.0	29.0	32.0	18.0	5.0	0.0	17.0	64.0	64.0
Cinà <i>et al.</i> 2002	121	0.0	14.0	19.8	23.1	43.0	0.0	18.2			
Conrad <i>et al.</i> 2011	179	0.0	40.8	17.3	41.9	0.0	0.0		9.9		
Corvera <i>et al.</i> 2012	93	29.0	24.7	39.8			0.0	5.4	15.1	72.0	60.1
Fehrenbacher <i>et al.</i> 2007a	173	36.4	15.6	28.3	11.6	8.1	0.0	10.4		67.0	66.1
Fehrenbacher <i>et al.</i> 2007b	33	0.0	0.0	0.0	57.6	42.4	0.0	6.1	24.2	72.7	70.0
Fehrenbacher <i>et al.</i> 2010	343	28.6	20.1	32.4	9.3	9.6	0.0	13.1	15.5	63.6	66.0
Fleck <i>et al.</i> 2005	17	0.0	11.8	70.6	17.6	0.0	0.0		18.0	58.8	67.2
Harky <i>et al.</i> 2021	430	36.5	63.5					35.1	14.0	66.0	63.0
Hassoun <i>et al.</i> 2004	81	0.0	9.9	51.9	16.0	19.8	2.5		25.9	59.3	
Henmi <i>et al.</i> 2022	294	0.0	8.5	34.4	42.2	10.5	0.0		84.6	71.5	63.4
Huang <i>et al.</i> 2022	26		0.0	69.2	3.8	0.0	26.9			85.0	50.0
Jacobs <i>et al.</i> 1998	73	0.0	37.0	38.4	11.0	13.7	0.0	23.3	5.5	63.0	59.0
Kahlberg <i>et al.</i> 2021	90	0.0	11.1	36.7	27.8	24.4	0.0		30.0	68.9	65.1
Karlsson <i>et al.</i> 2022	33	0.0									
Kawaharada <i>et al.</i> 2002	37	0.0	10.8	35.1	27.0	27.0	0.0				
Kawaharada <i>et al.</i> 2004	100	0.0	24.0	24.0	35.0	17.0	0.0	0.0		70.0	61.0
Koksoy <i>et al.</i> 2002	30	0.0	0.0	100.0	0.0	0.0	0.0	16.7	26.7		
Kouchoukos <i>et al.</i> 2013	243	0.0	25.9	39.9	34.2	0.0	0.0	7.4		49.0	64.0
Kouchoukos <i>et al.</i> 2015	69	0.0	18.8	59.4	21.7	0.0	0.0		13.0	77.0	54.0
Kouchoukos <i>et al.</i> 2019	285	0.0	25.3	37.5	36.5	0.7	0.0	6.7	15.4		64.0
Kulik <i>et al.</i> 2011	218	0.0	26.1	41.7	32.1	0.0	0.0	8.3	13.8	50.0	63.0
Kunihara <i>et al.</i> 2009	17	0.0	17.6	29.4	23.5	23.5	5.9			59.0	64.0
Kunihara <i>et al.</i> 2021	182	0.0	30.8	18.7	23.6	9.3	17.6		27.5	66.4	68.0
Leijdekkers <i>et al.</i> 1999	11	0.0	0.0	100.0	0.0	0.0	0.0				
LeMaire <i>et al.</i> 2002	1220	0.0	34.7	30.4	16.5	18.4	0.0		25.0		
LeMaire <i>et al.</i> 2009	172	0.0	0.0	91.9	8.1	0.0	0.0	2.9	15.0	62.0	62.5
Mastroroberto <i>et al.</i> 1999	19	0.0	63.2	15.8	5.3	15.8	0.0	100.0			67.1
Mkalaluh <i>et al.</i> 2018	38	0.0	31.6	57.9	7.9	2.6	0.0	21.1	23.7	42.1	54.4
Morishita <i>et al.</i> 1999	73	0.0	12.3	17.8	46.6	23.3	0.0	9.6			
Nishi <i>et al.</i> 2004	17	0.0	52.9	47.1	0.0	0.0	0.0	5.9	11.8	65.0	
Palombo <i>et al.</i> 2004	7	0.0	28.6	57.1	14.3	0.0	0.0			71.4	68.0
Safi <i>et al.</i> 1996	234	3.0	32.9	42.3			0.0		24.0	63.7	
Schepens <i>et al.</i> 1999	258	0.0	15.1	43.4	27.5	14.0	0.0	14.7	5.8	73.6	65.4
Soukiasian <i>et al.</i> 2005	59	16.9									
Tshomba <i>et al.</i> 2014	84	0.0	0.0	29.8	38.1	32.1	0.0		30.0	77.4	66.5
Wahlgren <i>et al.</i> 2017	90	47.8	12.2	21.1	15.6	1.1	2.2		8.0	78.8	60.0
Weiss <i>et al.</i> 2012	240	30.0	32.5	10.8	12.9	13.8	0.0	20.4	10.0	56.0	62.6
Welbom <i>et al.</i> 2000	37	0.0	16.2	27.0	10.8	21.6	0.0		57.0		
Wongkomrat <i>et al.</i> 2015	200	0.0	12.0	41.0	25.5	5.0	16.5	9.5		73.5	65.1
Zhang <i>et al.</i> 2016	81	0.0	0.0	100.0	0.0	0.0	0.0			75.3	39.4
Zhang <i>et al.</i> 2019	190	0.0	0.0	100.0	0.0	0.0	0.0		2.2	74.7	39.5

**Key**

Min Max

n = number of cases. All other figures % unless specified. CKD = Moderate or Severe Chronic Kidney Disease. Blank values indicate lack of reporting.

Manuscript for submission

## Interventions

### *Circulatory Support Strategies*

Three strategies of systemic circulatory support were identified within the 44 included studies (table 6). LHB was used in 24 studies (33 subgroups), DHCA in 17 studies (17 subgroups) and pCPB in 11 studies (12 subgroups). SACC was the primary strategy reported in 8 studies (9 subgroups). One study contained two patient subgroups that received mixed strategies of SACC and LHB. Two single-cohort observational studies featured mixed strategies of LHB and DHCA.

### *Selective Renal Perfusion Strategies*

SRP was employed as an adjunct to LHB in 20 studies (26 subgroups), utilising cold crystalloid solutions in 9 studies (11 subgroups), warm blood in 8 studies (8 subgroups) and cold blood in 7 studies (7 subgroups) (Table 5).

SRP was used alongside pCPB in 8 studies (9 subgroups), including warm blood in 8 subgroups, and cold crystalloid in 1. Five subgroups featured SACC with the adjunctive use of cold crystalloid SRP. Of five subgroups that utilised SRP with DHCA, four used cold blood and one used a cold crystalloid solution.

Manuscript for submission

**Table 5. Reported contents of crystalloid renal perfusates**

Study	Contents					
	Ringer's Lactate	Ringer's Acetate	Mannitol	Methylprednisolone	HTK solution	Undefined
Schepens <i>et al.</i> 1999		◆	◆			
Koksoy <i>et al.</i> 2002	◆		◆	◆		
Nishi <i>et al.</i> 2004						◆
Fleck <i>et al.</i> 2005	◆		◆	◆		
Lemaire <i>et al.</i> 2009	◆		◆	◆		
Conrad <i>et al.</i> 2011	◆		◆	◆		
Tshomba <i>et al.</i> 2014	◆		◆	◆	◆	
Wongkornrat <i>et al.</i> 2015						◆
Alfonsi <i>et al.</i> 2018		◆	◆	◆		
Kahlberg <i>et al.</i> 2021	◆		◆	◆	◆	
Huang <i>et al.</i> 2022	◆		◆	◆	◆	

Manuscript for submission

Table 6. Study Characteristics and Clinical Outcomes										
Study Characteristics						Clinical Outcomes				
Study	Year	Study Design	Sample Size	Primary ECC Type	SRP Technique	RRT (%)	p	30-day Mortality (%)	p	Additional Evidence of Renal Protection
Bavaria et al <sup>20</sup>	1995	ROS	45	LHB		13.3	NS	6.7	* <0.05	
			36	None		24.2		22.2		
Safi et al <sup>21</sup>	1996	ROS	90	LHB		6.7	NA			♦
			58	LHB	Warm Blood	29.3				
Jacobs et al <sup>22</sup>	1998	POS	33	LHB	Warm Blood <sup>1</sup>	9	NA	8.0	*	
			40	LHB	Warm Blood <sup>2</sup>	5				
Leijdekkers et al <sup>23</sup>	1999	POS	6	LHB	Warm Blood	33				
			5	LHB		40				
Mastroberto et al <sup>24</sup>	1999	ROS	19	pCPB		31.6	NA	42.1		
Morishita et al <sup>25</sup>	1999	ROS	41	pCPB <sup>3</sup>	Warm Blood	4.9	0.01	17.0	NS	
			22	pCPB <sup>4</sup>	Warm Blood	4.5		5.0		
			10	None		20		10.0		
Schepens et al <sup>26</sup>	1999	ROS	123	None	Cold Crystalloid	10.9	NS	14.6	* 0.02	
			135	LHB	Cold Crystalloid	5.9		5.9		
Welborn et al <sup>15</sup>	2000	POS	12	LHB		25	* NS	0.0	* NS	
			16	None		44		11.0		
Cina et al <sup>27</sup>	2002	POS	43	None	Cold Crystalloid	3	NS	26.6	* 0.01	
			78	LHB	Cold Blood	16		5.7		
Kawaharada et al <sup>28</sup>	2002	ROS	37	pCPB	Warm Blood	22.2	NA	14.8		
Koksoy et al <sup>29</sup>	2002	CT	16	LHB	Warm Blood	6.3	NS	6.3	*	
			14	LHB	Cold Crystalloid	0		7.1		
LeMaire et al <sup>30</sup>	2002	ROS	78	None	Cold Crystalloid	3	NS	6.0	NS	♦
			34	LHB	Warm Blood	13		22.0		
Hassoun et al <sup>31</sup>	2004	ROS	44	LHB	Cold Blood	23.4				
			37	LHB	Warm Blood	21.6				
Kawaharada et al <sup>32</sup>	2004	ROS	100	pCPB	Warm Blood	16.2	NA	5.4		
Nishi et al <sup>33</sup>	2004	ROS	9	pCPB	Cold Crystalloid	11.1	NR	11.1	*	
			8	DHCA	Cold Crystalloid	0		12.5		
Palombo et al <sup>34</sup>	2004	ROS	7	pCPB	Warm Blood	0	NA	5.9	*	
Fleck et al <sup>35</sup>	2005	ROS	17	LHB	Cold Crystalloid	12	NA	0.0	*	
Soukiasian et al <sup>36</sup>	2005	ROS	39	DHCA				5.0	NS	♦
			20	LHB				20.0		
Fehrenbacher et al <sup>37</sup>	2007a	ROS	173	DHCA	Cold Blood	1.2	NA	4.0	*	
Fehrenbacher et al <sup>38</sup>	2007b	ROS	33	DHCA	Cold Blood	0	NA	3.0	*	
Kunihara et al <sup>39</sup>	2009	POS	17	pCPB	Warm Blood	0	NA	0.0	*	
LeMaire et al <sup>40</sup>	2009	CT	86	LHB	Cold Blood	3	NS	7.0	NS	

Manuscript for submission

			86	LHB	Cold Crystalloid	3		5.0		
Fehrenbacher et al <sup>41</sup>	2010	ROS	343	DHCA		1.5	NA	4.4		
Conrad et al <sup>42</sup>	2011	ROS	52	LHB		8	*	2.0	*	NS
			127	None	Cold Crystalloid	17		5.0		
Kulik et al <sup>43</sup>	2011	ROS	218	DHCA		6.9	NA	7.3		
Corvera et al <sup>44</sup>	2012	ROS	93	DHCA	Cold Blood	0	NA	2.2	*	
Weiss et al <sup>45</sup>	2012	ROS	45	DHCA		0	NS	8.9	NS	♦
			28	pCPB		7.1		7.1		
Kouchoukos et al <sup>46</sup>	2013	ROS	243	DHCA		3.6	NA	7.8		
Tshomba et al <sup>47</sup>	2014	ROS	42	LHB, None	Cold Crystalloid	2.4	NA	9.5	NS	♦
			42	LHB, None	Cold HTK	7.2		2.4		
Kouchoukos et al <sup>48</sup>	2015	ROS	69	DHCA		4.5	NA	5.8		
Wongkornrat et al <sup>49</sup>	2015	ROS	200	LHB	Cold Crystalloid	2.5	NA	3.0		
Zhang et al <sup>50</sup>	2016	ROS	81	DHCA		7.4	NA	7.4	*	
Wahlgren et al <sup>51</sup>	2017	ROS	57	LHB	Cold Blood	33	NS	10.5	NS	
			33	DHCA		15		6.1		
Alfonsi et al <sup>52</sup>	2018	ROS	173	LHB	Cold Crystalloid	4.6	NA	5.2	NS	
			41	DHCA		7.3		9.7		
Mkalaluh et al <sup>53</sup>	2018		38	pCPB	Warm Blood	10.5	NA	10.5		
Kouchoukos et al <sup>54</sup>	2019	ROS	285	DHCA		6.3	NA	7.4		
Zhang et al <sup>55</sup>	2019	ROS	58	DHCA		13.8	NS	6.9	<0.05	
			58	pCPB		3.4		0.0		
Harky et al <sup>56</sup>	2021	ROS	273	LHB, DHCA	Cold Blood	22.7	NA	9.9		
Kahlberg et al <sup>57</sup>	2021	CT	45	LHB	Cold HTK	2.3	NS	6.7	NS	♦
			45	LHB	Cold Crystalloid	13.6		13.3		
Kunihara et al <sup>58</sup>	2021	ROS	182	LHB, DHCA	Warm Blood	12.1	NA	11.0		
Bianchi et al <sup>59</sup>	2002	POS	100	LHB		8	NA	8.0	*	
Henmi et al <sup>60</sup>	2022	ROS	281	pCPB	Warm Blood	12.8	NA	8.2	*	
Huang et al <sup>61</sup>	2022	ROS	26	LHB	Cold Crystalloid/HTK	7.7	NA	15.4		
Karlsson et al <sup>62</sup>	2022	POS	21	LHB	Cold Blood	33	NS	5.0	*	NS
			12	LHB	Cold Blood	8		0.0		

ROS= Retrospective observational study, POS= Prospective observational study, CT= Clinical trial. ♦ = Significant reduction in secondary AKI outcome. <sup>1</sup>= No pressure monitoring. <sup>2</sup>= Pressure monitoring. <sup>3</sup>=Roller pump. <sup>4</sup>=Centrifugal pump. p= Statistical significance. NS= Not significant. NA=Not applicable. NR = Not recorded. \*=Alternative metric used.



Manuscript for submission

## Outcome Measures

### *Acute Kidney Injury*

Several different metrics were identified for the diagnosis of AKI. Post-operative RRT was the most common outcome measure, reported in 39 out of 44 (88.6%) studies, whereas alternative forms of diagnosis were described in 14 (31.8%); these were diverse, and included the use of KDIGO criteria, serum creatinine changes and undefined 'acute renal failure'. As the incidence of RRT was reported in a majority of studies, it was selected as the primary metric of AKI. Alternate AKI outcomes were recorded if they facilitated the appropriate comparison of renal injury between cohorts within individual studies, or when the incidence of RRT was not reported. Findings are presented in table 6.

### *Operative Mortality*

30-day post-operative mortality was reported in 23 of 44 (52.3%) studies, and was designated as the primary metric for 'operative mortality'. However, alternative forms of 'in-hospital mortality' were also extracted from 19 (43.2%) studies, and were used to aid comparative subgroup analysis in the absence of 30-day mortality. 2 studies did not report mortality outcomes<sup>23</sup>.

## Outcomes by Perfusion Strategy

### *Distal Aortic Perfusion: Left Heart Bypass*

The use of LHB *without* adjunctive SRP was associated with a 5.0-40.0% incidence of post-operative RRT, and a 0-20.0% risk of operative mortality (figures 4, 5). When used *with* adjunctive SRP, LHB was associated with incidences of RRT ranging from 5.0% to 33.0% with the use of normothermic blood, 3.0% to 33.0% with cold blood, and 0% to 13.6% with cold crystalloid solutions. Operative mortality ranged from 6.3% to 22.0% with the use of warm blood SRP, 5.7% to 10.5% with cold blood, and 0% to 15.4% with cold crystalloid solutions.

## Manuscript for submission

Four studies between 1995 and 2011 demonstrated that LHB could be used to achieve superior outcomes than SACC. Bavaria and colleagues showed that LHB was associated with a reduced incidence of in-hospital mortality (6.7% vs 22.2%,  $p < 0.05$ )<sup>20</sup>. Schepens and colleagues found that LHB was associated with reduced risks of post-operative RRT (O.R. 0.08, 95% C.I. 0.01-0.6,  $p = 0.02$ ) and mortality (5.9% vs 14.6%,  $p < 0.02$ )<sup>26</sup>. LeMaire and colleagues showed that LHB could improve rates of AKI compared to SACC (9% vs 32%,  $p < 0.0005$ ), despite the adjunctive use of cold crystalloid SRP alongside SACC. This protection was also associated with non-significant reductions in RRT (3% vs 13%,  $p = 0.167$ ) and 30-day mortality (6% vs 22%)<sup>30</sup>. Similarly, Conrad and colleagues (2011) utilised propensity-matching to demonstrate that AKI (8% vs 17%,  $p = 0.10$ ) and in-hospital mortality (2% vs 5%,  $p = 0.38$ ) were lower with LHB than SACC with cold crystalloid SRP. However, their findings did not reach statistical significance<sup>42</sup>.

The adjunctive use of SRP has been employed alongside LHB in several studies, to varying degrees of success. Warm blood SRP is generally associated with inferior outcomes, whereas renal cooling has been shown to provide effective kidney protection. Safi and colleagues compared LHB with warm blood SRP to a non-adjunctive strategy of LHB, and identified warm blood SRP as a risk factor for AKI, associated with a four-fold increase in its incidence<sup>21</sup>. Similarly, Koksoy and colleagues compared warm blood SRP to cold crystalloid SRP during LHB to find that warm blood SRP was associated with a three-fold rise in AKI (63% vs 21%,  $p = 0.03$ )<sup>29</sup>. Hassoun and colleagues (2004) compared the use of warm and cold blood SRP during LHB, discovering that cold blood SRP was associated with a significantly lower incidence of operative mortality (27% vs 56%,  $p < 0.02$ ), despite no significant differences in recovery from renal dysfunction during hospitalisation (27% warm vs 36% cold,  $p = 0.37$ )<sup>31</sup>. In a clinical trial, LeMaire and colleagues compared intermittent boluses of cold blood or crystalloid solution with additives mannitol and methylprednisolone during LHB. They found that the rate of RRT was identical in both cohorts (3.0% vs

Manuscript for submission

3.0%,  $p=1.0$ ), and there was no difference in the incidence of 30-day mortality (7.0% blood vs 5.0% crystalloid,  $p=0.7$ )<sup>40</sup>.

There is some evidence that the contents of crystalloid perfusates can affect kidney protection. In a 2021 clinical trial, Kahlberg and colleagues compared the use of HTK solution to a Ringer's-based crystalloid perfusate, demonstrating a lower incidence of KDIGO AKI with HTK solution (48.9% vs 75.6%,  $p=0.02$ ), though rates of RRT were lower but not significantly different (2.2% vs 13.3%,  $p=0.11$ )<sup>57</sup>. Furthermore, no significant difference in 30-day mortality was identified (6.7% HTK vs 13.3% Ringer's,  $p=0.23$ )<sup>57</sup>.

#### Distal Aortic Perfusion: Partial Cardiopulmonary Bypass

The use of pCPB has also been shown to provide superior renal protection than SACC. Morishita and colleagues demonstrated that pCPB with adjunctive warm blood SRP could be used to significantly reduce the risk of RRT, irrespective of the type of blood pump used for circulatory support (4.5% centrifugal pump, 4.9% roller pump, 20% SACC,  $p=0.01$ ). pCPB was also associated with higher intraoperative urine production (2.9ml/hr roller SRP, 2.8ml/hr centrifugal SRP, 0.2ml/hr SACC) and lower post-operative serum creatinine concentrations ( $p<0.0001$ ) than SACC<sup>25</sup>.

With a small cohort of patients, Kunihara and colleagues (2009) achieved no incidences of RRT or operative mortality with pCPB and warm blood SRP<sup>39</sup>. More recently, Henmi and colleagues (2022) analysed the results from 281 cases to show that 150-200ml/min of warm blood SRP per renal artery was associated with a 12.8% incidence of RRT, a 63.3% incidence of KDIGO AKI and an 8.2% risk of in-hospital mortality<sup>60</sup>.

A propensity-matched study by Zhang and colleagues (2019) compared pCPB to DHCA and showed that whilst pCPB was associated with lower risks of RRT (3.4% vs 13.8%,  $p=0.047$ ) and 30-day mortality (0% vs 6.9%,  $p<0.05$ ), there was no significant difference in the rate of new-onset renal insufficiency (13.8% vs

## Manuscript for submission

24.1%,  $p=0.126$ )<sup>55</sup>. Similarly, an earlier propensity-matched comparison study from Weiss and colleagues (2012) found no significant difference in the rate of RRT following pCPB or DHCA, though DHCA was associated with a lower incidence of AKI (22.2% vs 46.4%,  $p=0.03$ )<sup>63</sup>. Notably, a higher proportion of DHCA patients received DTA repair (22% vs 42%,  $p=0.04$ ), which is generally associated with reduced renal ischaemic times than TAAA repair.

### Deep Hypothermic Circulatory Arrest

The use of DHCA is associated with low incidences of RRT (0-15.0%) and operative mortality (2.2-12.5%). Soukiasian and colleagues (2005) compared DHCA to LHB and demonstrated that a reduced incidence of AKI, defined by a 1.5-fold increase in serum creatinine concentration, was associated with DHCA (0% vs 15%,  $p=0.04$ )<sup>36</sup>. However, the use of DHCA has not been evaluated in high-quality research, and was not compared to SACC in any studies.

Manuscript for submission




Figure 4. The reported incidence of post-operative renal replacement therapy by study, according to strategies of circulatory support and selective renal perfusion. pCPB- partial cardiopulmonary bypass; LHB- left heart bypass; DHCA- cardiopulmonary bypass with deep hypothermic circulatory arrest.




Figure 5. The reported incidences of 30-day and in-hospital mortality by study, according to strategies of circulatory support and selective renal perfusion. pCPB- partial cardiopulmonary bypass; LHB- left heart bypass; DHCA- cardiopulmonary bypass with deep hypothermic circulatory arrest.

Manuscript for submission to EJCTS

## **Discussion**

Surgical repair of the TAA is a rare, life-saving procedure. However, it is complicated by a significant risk of severe AKI, which is in turn associated with a requirement for post-operative RRT and increased risk of early mortality. We assessed the findings of 44 published studies to identify that TAA surgery is associated with highly variable incidences of 0-40% post-operative RRT and 0-42.1% operative mortality.

Perfusion strategies can be used to provide systemic circulatory support during surgical repair. These strategies include LHB or pCPB for DAP, and full cardiopulmonary bypass with DHCA. Furthermore, all strategies can be supplemented with selective perfusion of the renal arteries, using warm blood, cold blood or cold crystalloid solutions.

In order to establish the strength of evidence in support of each perfusion strategy, we performed a quality analysis of all studies. A majority of studies were deemed to present a low certainty of evidence, with 34 studies being of retrospective design and 22 featuring a single form of perfusion strategy. Few randomised clinical trials have been conducted in this field, making it difficult to directly compare the efficacy of alternative perfusion strategies. Furthermore, the 28-year time period encompassing the publication of included studies was host to an evolution in the criteria used to define AKI, meaning that the findings of this review should be interpreted with caution.

### Distal Aortic Perfusion Improves Kidney Protection

Our analysis demonstrates that normothermic perfusion of the distal aorta provides superior kidney protection than SACC. LHB and pCPB can both be used to provide DAP, perfuse the kidneys during aortic clamping and effectively reduce exposure to renal IRI. DAP can eliminate renal IRI during DTA or extent I TAA repairs, as clamping of the infra-renal aorta is not required, and perfusion of the kidneys is maintained

Manuscript for submission to EJCTS

for the duration of surgery. During the repair of aneurysms of greater extent, however, infra-renal clamping may be required, meaning that renal IRI is unlikely to be avoided with an isolated strategy of DAP.

### Selective Renal Perfusion Requires Further Optimisation

When DAP cannot prevent kidney ischaemia, the renal arteries may be directly cannulated to facilitate perfusion of the kidneys with blood or crystalloid solutions. SRP may feature normothermic blood to support kidney oxygenation, or cold perfusates to enable hypothermic renal protection. Hypothermia is an established cryoprotection strategy, used during cardiopulmonary bypass to reduce cellular metabolism and associated oxygen demands<sup>64</sup>.

Our findings demonstrate that cold blood and crystalloid solutions - composed of lactated Ringer's solution, mannitol and methylprednisolone - can deliver equivalent protection from AKI and operative mortality<sup>40</sup>. Moreover, the use of HTK solution may further improve protection, and is linked to a low incidence of post-operative RRT<sup>57</sup>. However, such strategies should be used with caution as extensive use of cold perfusion and crystalloid solutions are associated with risks of systemic hypothermia and haemodilution respectively, and may expose patients to an increased risk of cardiac arrest during surgery. Furthermore, this risk may be augmented with HTK solution, which is cardioplegic in nature. Finally, cold fluids also expose the kidneys to a sudden warm, highly oxygenated environment on reperfusion, which may exacerbate renal injury<sup>65</sup>. Whilst cold SRP can therefore be used to improve renal protection and reduce the incidence of AKI following surgery, it should be used with caution as not to jeopardise patient safety.

The theoretical advantages of normothermic blood SRP include functional protection of the kidneys with a reduced associated risk of cardiac arrest. However, our findings demonstrate that its use is associated



Manuscript for submission to EJCTS

with inferior renal protection. The findings from the work of Safi et al. (1996), Koksoy et al. (2002) and Hassoun et al. (2004) collectively show that warm blood SRP used during LHB provides poor renal protection. When used with pCPB, warm blood SRP is associated with a similar incidence of post-operative RRT.

Yet, it is likely that historic applications of warm SRP were performed sub-optimally. The kidneys are metabolically active and typically receive a combined blood flow of 1200ml/min in normal physiology<sup>66</sup>. Within the studies of this review, the maximum flow rate provided to the kidneys was 300ml/min per artery<sup>29</sup>. Furthermore, studies typically employed the use of a branched catheter system to enable simultaneous perfusion of the superior mesenteric and celiac arteries, which could lead to preferential flow away from the kidneys due to high relative renal resistance. It is feasible that flow rates used in these studies did not provide a sufficient delivery of oxygen to meet the metabolic demands of the kidneys at normothermia. Within the related discipline of *ex vivo* renal perfusion for transplantation, human kidneys have been functionally perfused for 24 hours at a mean flow of 364ml/min per kidney, producing a mean urine output of 27.4ml/hr<sup>67</sup>. This represents a higher flow than that used in any of the studies included here. Whilst the clinical impact of normothermic perfusion cannot be determined from the results of this study, the findings demonstrate that functional renal protection can be achieved through perfusion at normothermia. To provide effective intraoperative kidney protection with normothermic blood SRP, pre-clinical research is needed to further optimise and evaluate its use. Furthermore, the incorporation of pulsatile flow may offer an additional advantage to kidney perfusion, but also requires further research and development prior to clinical implementation.

Deep Hypothermic Circulatory Arrest

Manuscript for submission to EJCTS

The establishment of deep hypothermia can reduce global metabolic demands and enable arrest of the systemic circulation. Several studies demonstrate a comparable standard of renal protection to the use of LHB with cold crystalloid SRP. However, the evidence for the use of DHCA is restricted to retrospective observational studies from a limited number of surgical centres. Furthermore, the use of DHCA can have additional implications on surgical morbidity, and post-operative recovery times are high, potentially making this strategy undesirable for use within a high-throughput centre. In the series of studies reported here, DHCA was the only assisted circulation strategy not able to achieve a 0% rate of operative mortality in any study. Prospective research into the use of this technique is required in order to determine the implications of its use.

#### Additional Risk Factors

Clamp-induced renal IRI is understood to be the primary cause of AKI following TAA surgery. However, additional risk factors are known to contribute to its onset, and should be considered when implementing or developing methods of kidney protection. In 2022, Kiser and colleagues identified intensive use of cell salvage during LHB as a risk factor for AKI and operative mortality<sup>68</sup>. The common strategy of reinfusing unwashed, salvaged blood into the patient circulation is a likely cause of significant intravascular haemolysis. Cardiotomy suction causes red blood cell damage and the release of free haemoglobin into plasma, which has been identified as a risk factor for AKI following the use of cardiopulmonary bypass and Extra-Corporeal Membrane Oxygenation (ECMO)<sup>69,70</sup>. Plasma free haemoglobin can scavenge nitric oxide present within the renal vascular endothelium, inhibit vasodilation and augment renal ischaemia. Furthermore, heme, a product of haemoglobin oxidation, has been shown to cause direct proximal tubular cell toxicity, and can trigger an inflammatory cascade leading to cell damage<sup>16,71</sup>. Haemolysis may therefore contribute to AKI via renal endothelial dysfunction, cellular toxicity and amplification of the inflammatory response to surgery. Additionally, evidence from contemporary research suggests that inadequate

Manuscript for submission to EJCTS

perfusion of the femoral arteries can generate peripheral ischaemia and attenuate the release of myoglobin from muscle, which is known to contribute to AKI<sup>72,73</sup>. The integration of perfusion devices that minimise blood damage and peripheral ischaemia is therefore key to providing a holistic system of care that reduces renal hypoxia and toxicity.

### Limitations and Recommendations

The screening, and quality assessment stages of this review were performed by a single reviewer, however, clinical outcomes were extracted by the consensus of two reviewers. The findings of this review are limited to reported outcomes of RRT, AKI and operative mortality. Successful perfusion requires an assessment of additional clinical outcomes, such as neurological protection, that this review does not provide.

### **Conclusion**

AKI is a significant complication of open TAA surgery and is linked to an increased risk of operative mortality. The pathophysiology of AKI is multifactorial, but most commonly induced by renal IRI, which may be compounded by the influence of intravascular haemolysis and myoglobinaemia. Distal aortic perfusion and adjunctive cold SRP can reduce the degree of renal IRI generated by clamping of the aorta, and ameliorate the incidence of AKI. Cardiopulmonary bypass with DHCA may provide an excellent level of kidney protection, but is supported by low-quality evidence and may be associated with increased risks of alternative adverse outcomes, including low cardiac output syndrome and prolonged ventilator support<sup>74</sup>. Further, high-quality comparative research is necessary to establish its efficacy and limitations in relation to DAP and SRP. Normothermic blood SRP could offer physiological benefits that enable functional kidney protection, but pre-clinical research into the optimisation of this strategy is needed prior to its clinical implementation, to deliver safe and effective kidney protection during TAA surgery.

## References

- 1 Keyhani, K. *et al.* Analysis of motor and somatosensory evoked potentials during thoracic and thoracoabdominal aortic aneurysm repair. *J Vasc Surg* **49**, 36-41, doi:10.1016/j.jvs.2008.08.005 (2009).
- 2 Kemp, C. M., Feng, Z., Aftab, M. & Reece, T. B. Preventing spinal cord injury following thoracoabdominal aortic aneurysm repair: The battle to eliminate paraplegia. *JTCVS Tech* **8**, 11-15, doi:10.1016/j.xjtc.2021.01.046 (2021).
- 3 Coselli, J. S. & LeMaire, S. A. Left heart bypass reduces paraplegia rates after thoracoabdominal aortic aneurysm repair. *Ann Thorac Surg* **67**, 1931-1934; discussion 1953-1938, doi:10.1016/s0003-4975(99)00390-2 (1999).
- 4 Coselli, J. S., LeMaire, S. A., Koksoy, C., Schmittling, Z. C. & Curling, P. E. Cerebrospinal fluid drainage reduces paraplegia after thoracoabdominal aortic aneurysm repair: results of a randomized clinical trial. *J Vasc Surg* **35**, 631-639, doi:10.1067/mva.2002.122024 (2002).
- 5 Bonventre, J. V. & Yang, L. Cellular pathophysiology of ischemic acute kidney injury. *The Journal of clinical investigation* **121**, 4210-4221, doi:10.1172/JCI45161 (2011).
- 6 Wang, H. E., Muntner, P., Chertow, G. M. & Warnock, D. G. Acute kidney injury and mortality in hospitalized patients. *American journal of nephrology* **35**, 349-355, doi:10.1159/000337487 (2012).
- 7 Chatterjee, S. *et al.* Early-Stage Acute Kidney Injury Adversely Affects Thoracoabdominal Aortic Aneurysm Repair Outcomes. *Ann Thorac Surg* **107**, 1720-1726, doi:10.1016/j.athoracsur.2018.11.049 (2019).
- 8 Waked, K. & Schepens, M. State-of the-art review on the renal and visceral protection during open thoracoabdominal aortic aneurysm repair. *J Vis Surg* **4**, 31, doi:10.21037/jovs.2018.01.12 (2018).
- 9 Aftab, M. & Coselli, J. S. Renal and visceral protection in thoracoabdominal aortic surgery. *J Thorac Cardiovasc Surg* **148**, 2963-2966 (2014).
- 10 Rouer, M. *et al.* Early Postoperative Renal Dysfunction Predicts Long-Term Renal Function Degradation after Type IV Thoracoabdominal Aortic Aneurysm Surgical Repair. *Ann Vasc Surg* **68**, 316-325, doi:10.1016/j.avsg.2020.04.072 (2020).
- 11 LeMaire, S. A., Price, M. D., Green, S. Y., Zarda, S. & Coselli, J. S. Results of open thoracoabdominal aortic aneurysm repair. *Ann Cardiothorac Surg* **1**, 286-292 (2012).
- 12 Basile, D. P., Anderson, M. D. & Sutton, T. A. Pathophysiology of acute kidney injury. *Compr Physiol* **2**, 1303-1353, doi:10.1002/cphy.c110041 (2012).
- 13 Schaub, J. A., Venkatachalam, M. A. & Weinberg, J. M. Proximal Tubular Oxidative Metabolism in Acute Kidney Injury and the Transition to CKD. *Kidney360* **2**, 355-364, doi:10.34067/KID.0004772020 (2021).
- 14 Bhargava, P. & Schnellmann, R. G. Mitochondrial energetics in the kidney. *Nat Rev Nephrol* **13**, 629-646, doi:10.1038/nrneph.2017.107 (2017).
- 15 Welborn, M. B. *et al.* The relationship between visceral ischemia, proinflammatory cytokines, and organ injury in patients undergoing thoracoabdominal aortic aneurysm repair. *Crit Care Med* **28** (2000).

- 16 Malek, M. & Nematbakhsh, M. Renal ischemia/reperfusion injury; from pathophysiology to treatment. *J Renal Inj Prev* **4**, 20-27, doi:10.12861/jrip.2015.06 (2015).
- 17 Yokoyama, N. *et al.* Acute Kidney Injury Following Elective Open Aortic Repair with Suprarenal Clamping. *Ann Vasc Dis* **13**, 45-51, doi:10.3400/avd.oa.19-00095 (2020).
- 18 Wynn, M. M., Acher, C., Marks, E., Engelbert, T. & Acher, C. W. Postoperative renal failure in thoracoabdominal aortic aneurysm repair with simple cross-clamp technique and 4 degrees C renal perfusion. *J Vasc Surg* **61**, 611-622, doi:10.1016/j.jvs.2014.10.040 (2015).
- 19 Tshomba, Y. *et al.* in *Visceral Vessels and Aortic Repair* Ch. Chapter 17, 195-205 (2019).
- 20 Bavaria, J. E., Woo, Y. J., Hall, R. A., Carpenter, J. P. & Gardner, T. J. Retrograde cerebral and distal aortic perfusion during ascending and thoracoabdominal aortic operations. *Ann Thorac Surg* **60**, 345-352; discussion 352 (1995).
- 21 Safi, H. J. *et al.* Predictive factors for acute renal failure in thoracic and thoracoabdominal aortic aneurysm surgery. *J Vasc Surg* **24**, 338-344; discussion 344-335, doi:10.1016/s0741-5214(96)70189-1 (1996).
- 22 Jacobs, M. J. *et al.* Reduced renal failure following thoracoabdominal aortic aneurysm repair by selective perfusion. *Eur J Cardiothorac Surg* **14**, 201-205 (1998).
- 23 Leijdekkers, V. J. *et al.* The visceral perfusion system and distal bypass during thoracoabdominal aneurysm surgery: an alternative for physiological blood flow? *Cardiovasc Surg* **7**, 219-224 (1999).
- 24 Mastroberto, P. & Chello, M. Emergency thoracoabdominal aortic aneurysm repair: Clinical outcome. *JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY* **118**, 477-481 (1999).
- 25 Morishita, K. *et al.* Selective visceral and renal perfusion in thoracoabdominal aneurysm repair. *Eur J Cardiothorac Surg* **15**, 502-507, doi:10.1016/s1010-7940(99)00075-5 (1999).
- 26 Schepens, M. A. A. M. *et al.* Impact of Left Heart Bypass on the Results of Thoracoabdominal Aortic Aneurysm Repair. Report No. 1998;27:5868, (1999).
- 27 Cina, C. S. *et al.* Thoracoabdominal aortic aneurysm repair: a prospective cohort study of 121 cases. *Ann Vasc Surg* **16**, 631-638, doi:10.1007/s10016-001-0181-x (2002).
- 28 Kawaharada, N. *et al.* Thoracoabdominal or descending aortic aneurysm repair after preoperative demonstration of the Adamkiewicz artery by magnetic resonance angiography. *Eur J Cardiothorac Surg* **21**, 970-974, doi:10.1016/s1010-7940(02)00097-0 (2002).
- 29 Köksoy, C. *et al.* Renal perfusion during thoracoabdominal aortic operations: cold crystalloid is superior to normothermic blood. *Ann Thorac Surg* **73**, 730-738 (2002).
- 30 LeMaire, S. A., Rice, D. C., Schmittling, Z. C. & Coselli, J. S. Emergency surgery for thoracoabdominal aortic aneurysms with acute presentation. *J Vasc Surg* **35**, 1171-1178, doi:10.1067/mva.2002.123320 (2002).
- 31 Hassoun, H. T. *et al.* Cold visceral perfusion improves early survival in patients with acute renal failure after thoracoabdominal aortic aneurysm repair. *J Vasc Surg* **39**, 506-512, doi:10.1016/j.jvs.2003.09.040 (2004).
- 32 Kawaharada, N. *et al.* Thoracoabdominal aortic aneurysm repair through redo left-sided thoracotomy. *Ann Thorac Surg* **77**, 1304-1308, doi:10.1016/j.athoracsur.2003.09.043 (2004).

- 33 Nishi, H. *et al.* Extensive Thoracoabdominal Aortic Aneurysm Repair Using Deep Hypothermic Bypass and Circulatory Arrest. **12**, 69-74 (2004).
- 34 Palombo, D., Valenti, D., Gaggiano, A., Lupo, M. & Borin, P. Early experience with the minimal extracorporeal circulation system (MECC) during thoracoabdominal aortic aneurysm repair. *Eur J Vasc Endovasc Surg* **27**, 324-326 (2004).
- 35 Fleck, T. M. *et al.* Improved outcome in thoracoabdominal aortic aneurysm repair: the role of cerebrospinal fluid drainage. *Neurocrit Care* **2**, 11-16, doi:10.1385/NCC:2:1:011 (2005).
- 36 Soukiasian, H. J. *et al.* Total circulatory arrest for the replacement of the descending and thoracoabdominal aorta. *Arch Surg* **140**, 394-398, doi:10.1001/archsurg.140.4.394 (2005).
- 37 Fehrenbacher, J. W., Hart, D. W., Huddleston, E., Siderys, H. & Rice, C. Optimal end-organ protection for thoracic and thoracoabdominal aortic aneurysm repair using deep hypothermic circulatory arrest. *Ann Thorac Surg* **83**, 1041-1046 (2007).
- 38 Fehrenbacher, J., Siderys, H. & Shahriari, A. Preservation of renal function utilizing hypothermic circulatory arrest in the treatment of distal thoracoabdominal aneurysms (types III and IV). *Ann Vasc Surg* **21**, 204-207, doi:10.1016/j.avsg.2006.08.008 (2007).
- 39 Kunihara, T., Shiiya, N., Wakasa, S., Matsuzaki, K. & Matsui, Y. Assessment of hepatosplanchnic pathophysiology during thoracoabdominal aortic aneurysm repair using visceral perfusion and shunt. *Eur J Cardiothorac Surg* **35**, 677-683 (2009).
- 40 Lemaire, S. A. *et al.* Randomized comparison of cold blood and cold crystalloid renal perfusion for renal protection during thoracoabdominal aortic aneurysm repair. *J Vasc Surg* **49**, 11-19; discussion 19, doi:10.1016/j.jvs.2008.08.048 (2009).
- 41 Fehrenbacher, J. W., Siderys, H., Terry, C., Kuhn, J. & Corvera, J. S. Early and late results of descending thoracic and thoracoabdominal aortic aneurysm open repair with deep hypothermia and circulatory arrest. *J Thorac Cardiovasc Surg* **140**, S154-160; discussion S185 (2010).
- 42 Conrad, M. F. *et al.* Evolution of operative strategies in open thoracoabdominal aneurysm repair. *J Vasc Surg* **53**, 1195-1201 e1191, doi:10.1016/j.jvs.2010.11.055 (2011).
- 43 Kulik, A., Castner, C. F. & Kouchoukos, N. T. Outcomes after thoracoabdominal aortic aneurysm repair with hypothermic circulatory arrest. *J Thorac Cardiovasc Surg* **141**, 953-960, doi:10.1016/j.jtcvs.2010.06.010 (2011).
- 44 Corvera, J. S. & Fehrenbacher, J. W. Open repair of chronic aortic dissections using deep hypothermia and circulatory arrest. *Ann Thorac Surg* **94**, 78-81; discussion 82-73, doi:10.1016/j.athoracsur.2012.03.081 (2012).
- 45 Weiss, A. J., Pawale, A., Griep, R. B. & Di Luozzo, G. Deep versus mild hypothermia during thoracoabdominal aortic surgery. *Ann Cardiothorac Surg* **1**, 329-333, doi:10.3978/j.issn.2225-319X.2012.07.13 (2012).
- 46 Kouchoukos, N. T., Kulik, A. & Castner, C. F. Outcomes after thoracoabdominal aortic aneurysm repair using hypothermic circulatory arrest. *J Thorac Cardiovasc Surg* **145**, S139-141 (2013).
- 47 Tshomba, Y. *et al.* Comparison of renal perfusion solutions during thoracoabdominal aortic aneurysm repair. *J Vasc Surg* **59**, 623-633, doi:10.1016/j.jvs.2013.09.055 (2014).
- 48 Kouchoukos, N. T., Kulik, A. & Castner, C. F. Open thoracoabdominal aortic repair for chronic type B dissection. *J Thorac Cardiovasc Surg* **149**, S125-129, doi:10.1016/j.jtcvs.2014.07.064 (2015).

- 49 Wongkornrat, W. *et al.* Predictors of paraplegia with current thoracoabdominal aortic aneurysm repair. *Asian Cardiovasc Thorac Ann* **23**, 406-411 (2015).
- 50 Zhang, L., Sun, X. G., Yu, C. T., Chang, Q. & Qian, X. Y. Intercostal Artery Reconstruction: The Simple and Effective Technique on Spinal Cord Protection during Thoracoabdominal Aortic Replacement. *Ann Vasc Surg* **34**, 62-67 (2016).
- 51 Wahlgren, C. M., Blohmé, L., Günther, A., Nilsson, L. & Olsson, C. Outcomes of Left Heart Bypass Versus Circulatory Arrest in Elective Open Surgical Descending and Thoracoabdominal Aortic Repair. *Eur J Vasc Endovasc Surg* **53**, 672-678 (2017).
- 52 Alfonsi, J. *et al.* Open surgical repair of post-dissection thoraco-abdominal aortic aneurysms: early and late outcomes of a single-centre study involving over 200 patients. *Eur J Cardiothorac Surg* **54**, 382-388, doi:10.1093/ejcts/ezy050 (2018).
- 53 Mkalaluh, S. *et al.* Open surgical thoracoabdominal aortic aneurysm repair: The Heidelberg experience. *J Thorac Cardiovasc Surg* **156**, 2067-2073, doi:10.1016/j.jtcvs.2018.05.081 (2018).
- 54 Kouchoukos, N. T., Kulik, A., Haynes, M. & Castner, C. F. Early Outcomes After Thoracoabdominal Aortic Aneurysm Repair With Hypothermic Circulatory Arrest. *Ann Thorac Surg* **108**, 1338-1343 (2019).
- 55 Zhang, L. *et al.* Normothermic iliac perfusion improves early outcomes after thoracoabdominal aortic aneurysm repair. *Eur J Cardiothorac Surg* **55**, 1054-1060 (2019).
- 56 Harky, A. *et al.* Contemporary results of open thoracic and thoracoabdominal aortic surgery in a single United Kingdom center. *J Vasc Surg* **73**, 1525-1532 e1524, doi:10.1016/j.jvs.2020.09.027 (2021).
- 57 Kahlberg, A. *et al.* Renal perfusion with histidine-tryptophan-ketoglutarate compared with Ringer's solution in patients undergoing thoracoabdominal aortic open repair. *J Thorac Cardiovasc Surg*, - (2021).
- 58 Kuniyama, T., Vukic, C., Sata, F. & Schafers, H. J. Surgical Thoracoabdominal Aortic Aneurysm Repair in a Non-High-Volume Institution. *Thorac Cardiovasc Surg* **69**, 347-356, doi:10.1055/s-0040-1708470 (2021).
- 59 Bianchi, F. *et al.* Intraoperative neurophysiologic monitoring in thoracoabdominal aortic aneurysm surgery can provide real-time feedback for strategic decision making. *Neurophysiol Clin* **52**, 232-241, doi:10.1016/j.neucli.2021.12.006 (2022).
- 60 Henmi, S. *et al.* Acute Kidney Injury Affects Mid-Term Outcomes of Thoracoabdominal Aortic Aneurysms Repair. *Semin Thorac Cardiovasc Surg* **34**, 430-438, doi:10.1053/j.semtcvs.2021.04.050 (2022).
- 61 Huang, L. *et al.* The application of modular multifunctional left heart bypass circuit system integrated with ultrafiltration in thoracoabdominal aortic aneurysm repair. *Front Cardiovasc Med* **9**, 944287, doi:10.3389/fcvm.2022.944287 (2022).
- 62 Karlsson, L. *et al.* Novel method for direct retransfusion reduces blood transfusions in descending and thoracoabdominal aneurysm repair. *J Cardiovasc Surg (Torino)* **63**, 700-707, doi:10.23736/S0021-9509.22.12415-8 (2022).
- 63 Weiss, A. J. *et al.* A propensity score-matched comparison of deep versus mild hypothermia during thoracoabdominal aortic surgery. *J Thorac Cardiovasc Surg* **143**, 186-193, doi:10.1016/j.jtcvs.2011.07.020 (2012).

- 64 Saad, H. & Aladawy, M. Temperature management in cardiac surgery. *Glob Cardiol Sci Pract* **2013**, 44-62, doi:10.5339/gcsp.2013.7 (2013).
- 65 Hosgood, S. A., van Heurn, E. & Nicholson, M. L. Normothermic machine perfusion of the kidney: better conditioning and repair? *Transpl Int* **28**, 657-664, doi:10.1111/tri.12319 (2015).
- 66 Duke, J. in *Anesthesia Secrets* Ch. 44, 308 (Mosby Elsevier, 2011).
- 67 Weissenbacher, A. *et al.* Twenty-four-hour normothermic perfusion of discarded human kidneys with urine recirculation. *Am J Transplant* **19**, 178-192, doi:10.1111/ajt.14932 (2019).
- 68 Kiser, K. A. *et al.* Extensive cell salvage and postoperative outcomes following thoracoabdominal and descending aortic repair. *J Thorac Cardiovasc Surg* **163**, 914-921 e911, doi:10.1016/j.jtcvs.2020.06.005 (2022).
- 69 Vermeulen Windsant, I. C. *et al.* Hemolysis during cardiac surgery is associated with increased intravascular nitric oxide consumption and perioperative kidney and intestinal tissue damage. *Front Physiol* **5**, 340, doi:10.3389/fphys.2014.00340 (2014).
- 70 Vermeulen Windsant, I. C. *et al.* Hemolysis is associated with acute kidney injury during major aortic surgery. *Kidney international* **77**, 913-920, doi:10.1038/ki.2010.24 (2010).
- 71 Hanssen, S. J. *et al.* Visceral injury and systemic inflammation in patients undergoing extracorporeal circulation during aortic surgery. *Annals of surgery* **248**, 117-125, doi:10.1097/SLA.0b013e3181784cc5 (2008).
- 72 Bisdas, T. *et al.* Less-invasive perfusion techniques may improve outcome in thoracoabdominal aortic surgery. *J Thorac Cardiovasc Surg* **140**, 1319-1324, doi:10.1016/j.jtcvs.2010.01.012 (2010).
- 73 Miller, C. C., 3rd *et al.* Postoperative renal function preservation with nonischemic femoral arterial cannulation for thoracoabdominal aortic repair. *J Vasc Surg* **51**, 38-42, doi:10.1016/j.jvs.2009.08.044 (2010).
- 74 Yoo, J. S. *et al.* Deep hypothermic circulatory arrest versus non-deep hypothermic beating heart strategy in descending thoracic or thoracoabdominal aortic surgery. *Eur J Cardiothorac Surg* **46**, 678-684, doi:10.1093/ejcts/ezu053 (2014).



Manuscript for submission to EJCTS

## SUPPLEMENTARY INFORMATION

<b>Table S1: Full Literature Search Terms</b>	
Information Sources	PubMed Web of Science ClinicalTrials.gov EU Clinical Trials Register
Date range searched	01/01/1995 to 31/12/2023
Types of study to be included	Clinical Trial reports, prospective observational studies and retrospective observational studies.
Search Keywords	Thoracoabdominal, TAAA, Renal perfusion, Perfusion, Acute Kidney Injury, AKI, Renal dysfunction, Renal failure, Haemodialysis, Serum creatinine, Glomerular filtration rate, GFR
Database Search Queries	<p><b>PubMed:</b></p> <p>(((((Thoracoabdominal) OR (TAAA)) AND ((Perfusion) OR (CPB) OR (Bypass)) AND ((Renal) OR (Kidney) OR (AKI) OR (Haemodialysis) OR (Dialysis) OR (Creatinine) OR (GFR) OR (eGFR) OR (Glomerular)))) NOT ((Endovascular Techniques[MeSH Terms])))</p> <p><b>Clinicaltrials.gov:</b></p> <p>Condition or disease: Thoracoabdominal Aortic Aneurysm</p> <p>Other Terms: (Renal) AND (Repair OR Surgery) NOT (Endovascular OR Stent)</p> <p>Status: Completed OR Unknown status</p> <p>Age Group: Adult (18-64) OR Older adult (65+)</p> <p>Sex: All</p> <p><b>EU Clinical Trials Register:</b></p>

Manuscript for submission to EJCTS

	<p>Search Terms: Thoracoabdominal AND Renal NOT (Endovascular OR Stent) Age Range: Adult Trial Status: Completed</p> <p><b>Web of Science:</b></p> <p>((ALL=(Thoracoabdominal OR TAAA)) AND ALL=(Perfusion OR CPB OR Bypass)) AND ALL=(Renal OR Kidney OR AKI OR Haemodialysis OR dialysis OR Creatinine OR GFR OR glomerular)) NOT TS=(Endovascular Techniques)</p>
--	--